Triple-action diabetes jab delivers major weight and sugar reductions
TL;DR Summary
Phase 3 results show retatrutide, a weekly triple-hormone jab targeting GLP-1, GIP and glucagon, significantly lowers HbA1c and promotes substantial weight loss in type 2 diabetes after 40 weeks (HbA1c down ~1.7–1.9 points; weight loss ~11.5–15.3% vs 2.6% placebo), with mostly mild-to-moderate side effects. The drug could offer greater improvements than current therapies, but head-to-head trials and long-term data are still needed.
- Triple-action diabetes jab shown to reduce blood sugar and body weight The Guardian
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits Reuters
- ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Fierce Biotech
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications investor.lilly.com
- Lilly shares safety, tolerability data on its next-gen obesity drug statnews.com
Reading Insights
Total Reads
0
Unique Readers
33
Time Saved
3 min
vs 3 min read
Condensed
89%
563 → 62 words
Want the full story? Read the original article
Read on The Guardian